Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

NCT03047213 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

17

Enrollment

NIH

Sponsor class

Conditions

Locally Advanced Bladder Urothelial Carcinoma
Metastatic Transitional Cell Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Bladder Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Stage IV Bladder Urothelial Carcinoma AJCC v7

Interventions

DRUG: Sapanisertib

Sponsor

National Cancer Institute (NCI)